Precision medicine for adrenal cancer, study suggests
Wednesday, March 18, 2015 - 09:00
in Health & Medicine
In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.